'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa

Bianca Sossen, Tobias Broger, Andrew D Kerkhoff, Charlotte Schutz, Andre Trollip, Emmanuel Moreau, Samuel G Schumacher, Rosie Burton, Amy Ward, Robert J Wilkinson, David A Barr, Mark P Nicol, Claudia M Denkinger, Graeme Meintjes

Research output: Contribution to journalReview article

Abstract

Reducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97%.

Fingerprint

South Africa
Tuberculosis
HIV
Urine
Mortality
Survival
lipoarabinomannan

Cite this

Sossen, Bianca ; Broger, Tobias ; Kerkhoff, Andrew D ; Schutz, Charlotte ; Trollip, Andre ; Moreau, Emmanuel ; Schumacher, Samuel G ; Burton, Rosie ; Ward, Amy ; Wilkinson, Robert J ; Barr, David A ; Nicol, Mark P ; Denkinger, Claudia M ; Meintjes, Graeme. / 'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
@article{ac95f223ab9c4b7799ad9fae16f9d860,
title = "'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa",
abstract = "Reducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89{\%} who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97{\%}.",
author = "Bianca Sossen and Tobias Broger and Kerkhoff, {Andrew D} and Charlotte Schutz and Andre Trollip and Emmanuel Moreau and Schumacher, {Samuel G} and Rosie Burton and Amy Ward and Wilkinson, {Robert J} and Barr, {David A} and Nicol, {Mark P} and Denkinger, {Claudia M} and Graeme Meintjes",
year = "2020",
month = "1",
day = "9",
doi = "10.1093/cid/ciaa024",
language = "English",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa. / Sossen, Bianca; Broger, Tobias; Kerkhoff, Andrew D; Schutz, Charlotte; Trollip, Andre; Moreau, Emmanuel; Schumacher, Samuel G; Burton, Rosie; Ward, Amy; Wilkinson, Robert J; Barr, David A; Nicol, Mark P; Denkinger, Claudia M; Meintjes, Graeme.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 09.01.2020.

Research output: Contribution to journalReview article

TY - JOUR

T1 - 'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa

AU - Sossen, Bianca

AU - Broger, Tobias

AU - Kerkhoff, Andrew D

AU - Schutz, Charlotte

AU - Trollip, Andre

AU - Moreau, Emmanuel

AU - Schumacher, Samuel G

AU - Burton, Rosie

AU - Ward, Amy

AU - Wilkinson, Robert J

AU - Barr, David A

AU - Nicol, Mark P

AU - Denkinger, Claudia M

AU - Meintjes, Graeme

PY - 2020/1/9

Y1 - 2020/1/9

N2 - Reducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97%.

AB - Reducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97%.

U2 - 10.1093/cid/ciaa024

DO - 10.1093/cid/ciaa024

M3 - Review article

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -